Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 7, 2025
Daily News
March 7, 2025
- MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
March 7, 2025
- Govt’s Regulatory Reform Panel Discusses Access to Clinical Trial Information
March 7, 2025
- Novartis Adjusts Entresto Shipments Ahead of Price Hike in Off-Year Revision
March 7, 2025
- Off-Year Revision Is Problematic, Leads to Hesitation in Investment: Novo CEO
March 7, 2025
- Takeda’s Livmarli, BMS’s Camzyos, and More Inch Closer to Japan Approval
March 7, 2025
- Keytruda Tops Japan Drug Ranking for 17th Months on End: Encise
March 7, 2025
- Maruishi Files Midazolam Oral Syrup for Pediatric Use
March 7, 2025
- J&J Files Tremfya SC Induction Regimen for UC in Japan
March 7, 2025
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…